文献速递白血病造血干细胞移植与细胞治疗

老年AML异基因移植:是否存在最优预处理方案?

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
PubMed 文献 · Blood · 2020-01-01

该单中心研究纳入404例连续接受异基因造血干细胞移植的>60岁AML患者,比较四种预处理方案。倾向性评分分析显示,FM100组5年无进展生存率为49%,显著优于其他三组的30%、34%和23%,获益主要源于非复发死亡更低。

要点

  • >60岁AML患者接受FM100预处理者5年PFS达49%,优于其他方案。
  • FM100获益主要来自更低的非复发死亡,体能状态较差者更明显。
  • 倾向性评分分析确认FM100与更好的移植后生存相关。

核心结论

  • 老年AML患者接受含较低剂量美法仑的减低强度预处理FM100与更好的生存相关。

研究设计与样本

  • 单中心回顾性研究,连续纳入404例>60岁接受异基因造血干细胞移植的AML患者。
  • 比较四种预处理方案:FM100、FM140、Bu≥20000和Bu16000,采用倾向性评分分析比较结局。

主要发现

  • FM100组5年无进展生存率为49%,其他三组分别为30%、34%和23%。
  • FM100的生存获益主要源于非复发死亡更低,在体能状态较低的患者中更明显。
  • 倾向性评分分析确认FM100与更好的移植后生存相关,其他方案组间无显著差异。

关键数值与推荐

  • FM100方案:氟达拉滨+美法仑100 mg/m2。
  • FM140方案:氟达拉滨+美法仑140 mg/m2。
  • Bu≥20000方案:氟达拉滨+静脉白消安AUC≥5000/d×4天。
  • Bu16000方案:氟达拉滨+静脉白消安AUC 4000/d×4天。

临床怎么用

  • 对于>60岁AML患者,可考虑含较低剂量美法仑的减低强度预处理FM100。
  • 体能状态较差者可能从FM100中获益更明显。

局限性

  • 单中心回顾性研究,结果需外部验证。
  • FM100主要用于无法接受更强预处理的患者,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal conditioning regimen for older patients with acute myeloid leukemia (AML) remains unclear. In this study, we compared outcomes of AML patients >60 years of age undergoing allogenic hematopoietic stem cell transplantation at our institution. All 404 consecutively treated patients received 1 of the following conditioning regimens: (1) fludarabine+melphalan 100 mg/m2 (FM100), (2) fludarabine+melphalan 140 mg/m2 (FM140), (3) fludarabine+IV busulfan AUC ≥ 5000/d × 4 d (Bu≥20000), and (4) fludarabine+IV busulfan AUC 4000/d × 4 d (Bu16000). A propensity score analysis (PSA) was used to compare outcomes between these 4 groups. Among the 4 conditioning regimens, the FM100 group had a significantly better long-term survival with 5-year progression-free survival of 49% vs 30%, 34%, and 23%, respectively. The benefit of the FM100 regimen resulted primarily from the lower nonrelapse mortality associated with this regimen, an effect more pronounced in patients with lower performance status. The PSA confirmed that FM100 was associated with better posttransplantation survival, whereas no significant differences were seen between the other regimen groups. In summary, older patients with AML benefited from a reduced-intensity conditioning regimen with lower melphalan doses (FM100), which was associated with better survival, even though it was primarily used in patients who could not receive a more intense conditioning regimen.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ciurea SO, Kongtim P, Varma A, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020. PMID: 31826244. doi:10.1182/blood.2019003662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。